Abstract
Thioredoxin 1 (Trx1) is a small molecule with reactive cysteines that reduces proteins with disulfide bonds through a thiol disulfide exchange reaction. Accumulating lines of evidence suggest that Trx1 protects the heart from ischemia/reperfusion injury, pathological hypertrophy, and inflammation; induces preconditioning effects and angiogenesis; and upregulates mitochondrial genes. Exogenously given recombinant Trx1 (r-Trx1) may protect the heart through its actions in both extracellular and intracellular spaces. In this brief review, the potential of Trx1 therapy for heart disease is discussed. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure.".
| Original language | English (US) |
|---|---|
| Pages (from-to) | 570-573 |
| Number of pages | 4 |
| Journal | Journal of Molecular and Cellular Cardiology |
| Volume | 51 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2011 |
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Cardiology and Cardiovascular Medicine
Keywords
- Disulfide bond
- Ischemia/reperfusion
- Pathological cardiac hypertrophy
- Recombinant
- Small molecule
- Thioredoxin1
Fingerprint
Dive into the research topics of 'Application of recombinant thioredoxin1 for treatment of heart disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver